Drug Trial Radar · NCT06744205
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,162
Actual
Start
Jan 6, 2025
Primary completion
May 22, 2026
Study completion May 22, 2026
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
Conditions
- Influenza
- Healthy Volunteers
Interventions
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1Biological
* Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection
TIV mRNA-neuraminidase (NA)Biological
* Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection
TIV mRNA-HA Vaccine 2Biological
* Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection
Quadrivalent Influenza Standard Dose VaccineBiological
* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection
Quadrivalent Influenza Vaccine High DoseBiological
* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate unsolicited systemic adverse events (AEs)Time frame: Within 30 minutes after injection
- Number of participants with solicited injection site reactionsTime frame: Up to 7 days after injection
- Number of participants with solicited systemic reactionsTime frame: Up to 7 days after injection
- Number of participants with unsolicited AEsTime frame: Up to 28 days after injection
- Number of participants with medically attended adverse events (MAAEs)Time frame: Up to 180 days after injection
- Number of participants with serious adverse events (SAEs)Time frame: SAEs throughout the study (Up to approximately 12 months)
- Number of participants with adverse events of special interest (AESIs)Time frame: AESIs throughout the study (Up to approximately 12 months)
- Number of participants with out-of-range biological test resultsTime frame: Up to 8 days after injection
- Hemagglutinin inhibition (HAI) titersTime frame: At Day 1 and Day 29
- Individual HAI antibody (Ab) titer ratio D29/D01Time frame: At Day 1 and Day 29
- Seroconversion (HAI Ab titer)Time frame: At Day 1 and Day 29
- HAI Ab titer ≥ 40 (1/dil)Time frame: At Day 29
- Neuraminidase inhibition (NAI) titersTime frame: At Day 1 and Day 29
- Individual NAI Ab titer ratio D29/D01Time frame: At Day 1 and Day 29
- Seroconversion (NAI Ab titer)Time frame: At Day 1 and Day 29
- NAI Ab titer ≥ 40 (1/dil)Time frame: At Day 29
- 2-fold and 4-fold rise in NAI titersTime frame: Day 1 to Day 29
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Accel Research Sites Network - Birmingham- Site Number : 8400008
Birmingham, Alabama
AMR Mobile- Site Number : 8400022
Mobile, Alabama
Alliance for Multispeciality Research - Clinical Research Consortium- Site Number : 8400015
Tempe, Arizona
AMR Miami- Site Number : 8400021
Coral Gables, Florida
Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400003
DeLand, Florida
Alliance for Multispeciality Research - Fort Myers- Site Number : 8400013
Fort Myers, Florida
Accel Research Sites - Maitland- Site Number : 8400007
Maitland, Florida
Innovation Medical Research Center - Palmetto Bay- Site Number : 8400011
Palmetto Bay, Florida
Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400001
Decatur, Georgia
AMR - Chicago- Site Number : 8400012
Oak Brook, Illinois
Alliance for Multispeciality Research - Newton- Site Number : 8400020
Newton, Kansas
Alliance for Multispeciality Research - Wichita East- Site Number : 8400014
Wichita, Kansas
Alliance for Multispeciality Research - Lexington- Site Number : 8400018
Lexington, Kentucky
Boston Clinical Trials- Site Number : 8400009
Boston, Massachusetts
ActivMed Practices & Research- Site Number : 8400005
Methuen, Massachusetts
Quest Research Institute- Site Number : 8400010
Farmington Hills, Michigan
Alliance for Multispeciality Research - Kansas City- Site Number : 8400019
Kansas City, Missouri
AMR Las Vegas - Site Number : 8400016
Las Vegas, Nevada
Coastal Carolina Research Center - North Charleston- Site Number : 8400002
North Charleston, South Carolina
Alliance for Multispeciality Research - Knoxville- Site Number : 8400017
Knoxville, Tennessee
Charlottesville Medical Research- Site Number : 8400004
Charlottesville, Virginia
Investigational Site Number : 0360001
Botany, New South Wales, Australia
Investigational Site Number : 0360003
Bayswater, Victoria, Australia
Investigational Site Number : 0360002
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.